A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)

Trial Profile

A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Selinexor (Primary)
  • Indications Liposarcoma
  • Focus Registrational; Therapeutic Use
  • Acronyms SEAL
  • Sponsors Karyopharm Therapeutics
  • Most Recent Events

    • 08 Aug 2017 According to a Karyopharm Therapeutics media release, both the trial design and endpoints of this study have been accepted by the FDA and the European Medicines Agency.
    • 08 Aug 2017 According to a Karyopharm Therapeutics media release, the phase 2 portion of this study recently completed enrollment and the company expects to report the hazard ratio for progression-free survival from this phase 2 portion and an update regarding the planned development path in this indication during September or October 2017.
    • 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top